This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
The facility is spread across 215000 sq. feet and provides super-speciality care
Subscribe To Our Newsletter & Stay Updated
